Abstract:
A split body, rotary C gate, removeable stem vacuum valve using an input assembly with handle extensions that allow for hand movement of the incoming pipe to access an inner aperture body with a curved sealing face that directly seals to a C shaped gasketless gate that can be rotated into and out of the inner body aperture for easy cleaning. The gasketless gate is held in position using gate axles with an outer axle stem connected to a polygon lower body that mates into a matching polygon aperture on the gasketless gate. The middle valve assembly's gasketless housing body defines upper and lower axle washer pockets for locating the axles for proper operation and simple axle pins for securing the axles in position.
Abstract:
A method for preparing radiopharmaceutical complexes that are substantially free of the reaction materials used to produce the radiopharmaceutical complex is disclosed. The method involves admixing in a suitable first solvent in a container a target seeking ligand or salt or metal adduct thereof, a radionuclide label, and a reducing agent for said radionuclide, thereby forming said radiopharmaceutical complex; coating the interior walls of the container with said pharmaceutical complex; discarding the solvent containing by-products and unreacted starting reaction materials; and removing the radiopharmaceutical complex from said walls by dissolving it in a second solvent, thereby obtaining said radiopharmaceutical complex substantially free of by-products and unreacted starting materials.
Abstract:
A coordination complex comprising a radionuclide selected from the class consisting of radioactive isotopes of Tc, Ru, Co, Pt and Re and an isonitrile ligand of the formula:(CNX)R,where X is a lower alkyl group having 1 to 4 carbon atoms, wherein R is selected from the group consisting of COOR.sup.1 and CONR.sup.2 R.sup.3 where R.sup.1 can be H, a pharmaceutically acceptable cation, or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, R.sup.2, and R.sup.3 can be H, or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and R.sup.2 and R.sup.3 can be the same or different is disclosed. Kits that can be used to form these complexes are also disclosed.
Abstract:
A radiodiagnostic bisamido-bisthio ligand useful for producing Tc-labelled radiodiagnostic renal agents is described. The ligand forms a complex with the radionuclide .sup.99m Tc suitable for administration as a radiopharmaceutical to obtain images of the kidney for diagnosis of kidney disfunction.
Abstract:
A split body, rotary C gate, removeable stem vacuum valve using an input assembly with handle extensions that allow for hand movement of the incoming pipe to access an inner aperture body with a curved sealing face that directly seals to a C shaped gasketless gate that can be rotated into and out of the inner body aperture for easy cleaning. The gasketless gate is held in position using gate axles with an outer axle stem connected to a polygon lower body that mates into a matching polygon aperture on the gasketless gate. The middle valve assembly's gasketless housing body defines upper and lower axle washer pockets for locating the axles for proper operation and simple axle pins for securing the axles in position.
Abstract:
The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.
Abstract:
Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
Abstract:
In order to chill foodstuffs and the like type of material a modular chilling unit is provided with a jacketed trough through which a chilled non-cryogenic coolant such as glycol is circulated, and wherein the material to be cooled is moved along the cooled trough using an auger. The chilling unit is arranged so that it can be mounted on another so that the material is transferred from one to another under the influence of gravity and so that the length of chilling path can be suitably elongated. The troughs are each rotatably supported by a structure which allows rotation to a near inverted position wherein jets of cleaning fluid can be ejected into the interior of the trough.
Abstract:
A hand disassembly rotational valve coupling for tool less manipulation by a user's hands and fingers using a coupling housing body defining an output seal aperture close to an output handle retention slot and slot lip, where the slot lip has a slot handle gap and an output seal retainer including a coupling handle ring with a first triangulated offset body retention ears and hand graspable handles separated by a ring handle gap for hand assembly and disassembly from the coupling housing body.
Abstract:
A coordination complex comprising a radionuclide selected from the class consisting of radioactive isotopes of Tc, Ru, Co, Pt and Re and an isonitrile ligand of the formula:(CNX)R,where X is a lower alkyl group having 1 to 4 carbon atoms, wherein R is selected from the group consisting of COOR.sup.1 and CONR.sup.2 R.sup.3 where R.sup.1 can be H, a pharmaceutically acceptable cation, or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms. R.sup.2, and R.sup.3 can be H, or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and R.sup.2 and R.sup.3 can be the same of different is disclosed. Kits that can be used to form these complexes are also disclosed.